Core Viewpoint - Guichuang Tongqiao (02190) reported significant growth in its interim results, with a notable increase in revenue and profit, driven by its vascular intervention product lines and international market expansion [1][2]. Financial Performance - The company achieved a revenue of 482 million RMB, representing a year-on-year increase of 31.69% [1]. - Gross profit reached 343 million RMB, up by 31.5% year-on-year [1]. - Shareholder profit attributable to the company was 121 million RMB, marking a 76% increase compared to the previous year [1]. - Basic earnings per share stood at 0.38 RMB [1]. Product Segmentation - 63.3% of the company's revenue came from neurovascular intervention products, while 36.7% was from peripheral vascular intervention products [1]. International Expansion - The company has been actively penetrating the European market, particularly in France, Germany, and Italy, while also exploring emerging markets such as Brazil, India, and South Africa [2]. - International business revenue for the first half of the year reached 15.72 million RMB, reflecting a year-on-year growth of 36.9% [2]. - As of mid-August, the company's overseas revenue had already reached approximately 25 million RMB, surpassing the total overseas revenue of 22.58 million RMB projected for the entire year of 2024, indicating potential for further growth in the second half of the year [2].
归创通桥涨超5% 上半年核心板块业务表现亮眼 海外布局打造新增长引擎